GET yields 4.26% · JNJ yields 2.14%● Live data
📍 JNJ pulled ahead of the other in Year 9
Combined, GET + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of GET + JNJ for your $10,000?
Getnet Adquirência e Serviços Para Meios de Pagamento S.A. operates in the acquiring and services market for means of payment regulated by the Council National Monetary Council and the Central Bank of Brazil. The company engages in the provision of accreditation services for retailer and service providers establishments to accept credit and debit cards; capturing, transmission, and processing of data and information; and installation, uninstallation, monitoring, supply, maintenance, and leasing of equipment used in transaction capture networks, such as point-of-sales devices, as well as acts as a distributor of telecommunication operators for the commercialization of telephony and data recharge digital credits. It is also involved in the management of payments and receipts made to establishments accredited to its network; development and selling or licensing of software; selling or distributing products and services from entities that provide registry information; provision of technical, commercial, and logistic infrastructure services for the business related to the receipt of bills from dealers, banks, and other collection documents; and issuing electronic currency. The company was formerly known as Farthi Empreendimentos e Participações S.A. and changed its name to Getnet Adquirência e Serviços para Meios de Pagamento S.A. in August 2014. The company was founded in 2003 and is headquartered in São Paulo, Brazil. Getnet Adquirência e Serviços para Meios de Pagamento S.A. is a subsidiary of PagoNxt Merchant Solutions, S.L.
Full GET Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.